Advertisement
Interested parties can access a live audio webcast and accompanying slidepresentation via the Internet by visiting the Investor Relations section ofthe Company's Web site at http://www.transdelpharma.com. An archivedpresentation will be available on the Web site for 30 days.
Advertisement
About Transdel Pharmaceuticals, Inc.
Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) is a specialtypharmaceutical company focused on the development and commercialization ofnon-invasive topically delivered medications. The Company's lead topical drug,Ketotransdel(TM), utilizes the Company's innovative patented proprietaryTransdel(TM) cream formulation technology to facilitate the passage ofketoprofen, an NSAID, through the skin barrier to reach targeted underlyingtissue where the drug exerts its prolonged localized anti-inflammatory andanalgesic effect. The Company is also investigating other drug candidates andtreatments for transdermal delivery using the patented Transdel(TM) platformtechnology for products in pain management and other therapeutic areas.
Safe Harbor Statement
The statements which are not historical facts contained in this pressrelease are forward-looking statements that involve certain risks anduncertainties including but not limited to risks associated with theuncertainty of future financial results, additional financing requirements,development of new products, government approval processes, the impact ofcompetitive products or pricing, technological changes, the effect of economicconditions and other uncertainties detailed in the Company's filings with theSecurities and Exchange Commission.Contact: John Lomoro Chief Financial Officer Transdel Pharmaceuticals, Inc. 858-457-5300
SOURCE Transdel Pharmaceuticals, Inc.
